Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine; T-DM1)

NCT01983501 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01983501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01983501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine; T-DM1)
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
September 3, 2020
Enrollment
57 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive breast cancers